anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Risk Summary

The available data from the published literature over decades of use with diltiazem during pregnancy have not identified a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies, decreased embryo and fetal survival rates, and skeletal abnormalities have been observed at oral doses five to ten times the human oral antianginal therapeutic dose, and reduction in pup weights was also observed. At 20 times the human oral antianginal therapeutic dose, an increase in stillbirths was observed (see Data). 

The estimated background risk for major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies are 2% to 4% and 15% to 20%, respectively.

Data

Animal Data

Reproduction studies have been conducted in mice, rats, and rabbits. Administration of oral doses ranging from five to ten times greater (on a mg/kg basis) than the human oral antianginal therapeutic dose has resulted in embryo and fetal lethality. These doses, in some studies, have been reported to cause skeletal abnormalities. In the perinatal/postnatal studies there was some reduction in early individual pup weights and survival rates. There was an increased incidence of stillbirths at doses of 20 times the human oral antianginal therapeutic dose or greater.
Organisms, e.g. bacteria, which live in the human body and produce substances, e.g. as waste product, which blocks the receptor molecules from the HIV virus, and no longer docks the HIV virus, are new. The organisms are genetically modified organisms (including generic cells, bacteria and viruses) e.g. organisms, which produce other useful substances, e.g. fun-promoting substances such as tadalafil in the body, and substances that kill sperm or produce other beneficial substances in the body. Organisms, e.g. bacteria, which live in the human body and produce substances, e.g. as waste product, which blocks the receptor molecules from the HIV virus, and no longer docks the HIV virus, are new. The organisms are genetically modified organisms (including generic cells, bacteria and viruses) e.g. organisms, which produce other useful substances, e.g. fun-promoting substances such as tadalafil in the body, and substances that kill sperm or produce other beneficial substances in the body. The genetically modified organisms (including bacteria, viruses, normal body cells, e.g. cluster of differentiation (CD)8 T cells) feed through the genetic modification of undesirable bacteria/viruses, e.g. HIV virus. Substances such as enzymes, control the HIV virus, e.g. if these enzymes/substances produced by the body itself. These organisms live independently in the human body and make the production of functional substances. A production in tanks is not covered if the modified organism/the substance in the body does not make production themselves. The organisms that make the production in the body itself and/or outside of the body (for a higher efficiency) are detected, and the substances/organisms make HIV in monkeys as harmless as athlete's foot for humans. ACTIVITY : Anti-HIV. MECHANISM OF ACTION : None given.
A computer implemented method for controlling the intake of alimentation, such as medication or nutrition, in accordance with a time-based target comprises receiving data relating to the aliment being consumed, maintaining a balance of the alimentary constituent and generating a temporal estimate for the constituent. For example, the data relating to the amount of paracetomol consumed will be received, the total balance of paracetomol generated and the time that dose of paracetomol will last is calculated. The time take for groups of nutrients to be used by the body can also be calculated. A plurality of predictive temporal estimates are formed from the nutritional and pharmaceutical balances, enabling the user to make immediate and informed choices in real-time, to correct or fine-tune the alimentation in order to achieve or maintain dietary, medicinal and developmental goals. The system may be programmed to take account of the interaction between different foods and drugs and the lifestyle and genetics of the user. A mechanically-implemented system for controlling the intake of alimentation is also disclosed. The system may comprise rulers or gauges, such as slide rule, to assist with the calculation of temporal profiles.
BACKGROUND: Immunomodulatory therapies are becoming increasingly important in uro-oncology. For this reason, we will probably be increasingly confronted with side effects. In addition, there is an increasing number of combinations with other mechanisms of action. Immune-mediated side effects may occur as a consequence of this therapy. These are different from the side effects of chemotherapy and other targeted therapies and therefore require different treatment strategies.
AIM: Based on the current literature, the data on graduation and stage-dependent management will be presented as well as illustrated with examples from practice.
MATERIALS AND METHODS: Literature review on the detection and therapeutic management of adverse events mediated in the setting of immuno-oncologic therapy.
RESULTS: Treatment-related events can in principle affect all organ systems. Toxicities in the area of the skin, such as rash or pruritus, hypo- or hyperthyreosis, arthritis, muscle pain and gastrointestinal symptoms are frequently seen. In terms of frequency, most side effects are grade 1 to 2, but grade 3 to 4 toxicities are also generally well treatable if detected early. Rare complications such as neurological toxicities, pneumonitis or carditis can develop a fulminant course if diagnosed too late.
CONCLUSIONS: Even emergencies are manageable if we know the most important side effects and the therapeutic options. Immune-mediated side effects are of particular importance because they can affect any organ system. However, as long as we consider the possibility of toxicity from checkpoint inhibitors when the patient presents with symptoms, most side effects are easy to treat and therefore manageable.
Pancreatic ductal adenocarcinoma (PDAC) has a high recurrence rate even after radical resection because of subclinical tumors. To manage them, a reliable biomarker that can indicate the presence of subclinical tumors and predict their chemosensitivity is required. This study aimed to identify a miRNA as a biomarker that can be used to individualize postoperative adjuvant chemotherapy using postoperative peripheral blood samples. Integrating miRNA microarray data from the blood of 18 patients with PDAC and the in vitro results regarding the phenotypes of chemoresistant PDAC cells, a candidate miRNA was identified. The relationships between candidate miRNA expression and chemosensitivity were examined in vitro and in clinical samples from other cohorts of 33 patients with recurrence. Comprehensive analyses of blood samples detected 5 candidate miRNAs. Of these, miR-26a-5p was considered a candidate biomarker of chemosensitive phenotypes. In validation experiments, chemosensitivity was inversely correlated with miR-26a-5p expression in vitro. Moreover, the ability of miR-26a-5p to predict chemosensitivity was clinically evaluated using blood samples. Patients with high miR-26a-5p expression in the blood after radical resection exhibited a significantly longer survival time after recurrence. Thus, we concluded that miR-26a-5p is a potentially useful biomarker for managing patients with PDAC, especially those undergoing adjuvant chemotherapy.
NEW MATERIAL:A peptide shown by the formula I (Glx is Glu or Gln) having the following properties and its salt. Ultraviolet absorption spectrum: Max 280nm. Positive in Ehrlich reaction, Sakaguchi reaction, and Pauly's reaction. Basicity. Solubility: soluble in water methanol, and acetic acid, slightly soluble in ethyl acetate, butyl acetate, hexane, benzene, chloroform, etc. USE:A hormone agent for releasing growth hormone. Not only usable for remedying human microsomia and wound, but also useful as a growth promotor for livestock because it has no species specificity. PREPARATION:Each peptide chain is synthesized by active esterification method, DCC method, azide method, etc. In the operation, introduction of two or more peptides is carried out by azide method so that racemization is prevented, to give peptide chains shown by the formula II-IV (Glx is Glu or Gln), these peptide chains are condensed from the C terminal side, extended, and deprotected to give a peptide shown by the formula I .
OBJECTIVE: To observe the analgesic effects of Tuina on neuropathic pain (NPP) and the underlying mechanisms.
METHODS: Forty-eight Sprague-Dawley (SD) rats were assigned by random into three treatment groups: sham, chronic constriction injury (CCI), and Tuina. Each group contained sixteen rats. CCI model was generated by ligating the right sciatic nerve. Behavioral changes of CCI were assessed by the paw withdrawal threshold (PWT) and paw withdrawal latency (PWL). In addition, biochemical techniques such as immunofluorescence staining, enzyme-linked immunosorbent assay (ELISA) and Western blotting were used to profile levels of microglia activation and inflammatory factors in the spinal dorsal horn (SDH) of rats. Tuina (clockwise pressing and rubbing) was performed at Chengshan (BL57) to observe the analgesic effects on CCI rats and the underlying mechanisms.
RESULTS: Rats with CCI experienced significant reduction in the PWT and PWL of the right hind paw relative to CCI group at day 3. Tuina treatment rescued this situation significantly on days 10 and 14. Besides, Iba-1, microglia M1 receptor CD68, tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β) were higher in the right SDH for CCI group compared to the sham group on day 14. As expected, Tuina partially downregulated the CCI-induced overexpressed Iba-1, CD68, TNF-α, and IL-1β in the SDH of CCI model.
CONCLUSION: Tuina induces a time-dependent cumulative analgesic effect in CCI rats by inhibiting the activation of microglia and the secretion of IL-1β and TNF-α in SDH.
The STOP Persistent AF Post Approval Study (PAS) is a sub-study to the Cryo Global Registry. The PAS is a prospective, global, multicenter, observational trial. The purpose of the PAS is to describe long-term clinical performance and safety data in the Persistent AF population treated with Arctic Front™ and Freezor™ MAX Families of Cardiac Cryoablation Catheters (hereafter referred to as Arctic Front™ Cardiac Cryoablation Catheter System). This PAS is a condition of the Pre-Market Approval order (P100010/S098) by the U.S. Food and Drug Administration. Up to 400 subjects will be enrolled to ensure 355 are treated. A minimum of 50% of patients will be enrolled and treated in the US. The follow-up duration for this post-approval study will be 36-months.
Older adults in the US are in a difficult situation that is historically unprecedented. People born in 1930 were expected to live to age 59, yet they will live to an average age of 79. These dramatic survival increases, due to immunizations, antibiotics and other innovations \[Centers for Disease, 2011\], have occurred at the same time as dramatic reductions in daily energy expenditures, due to automobiles, washing machines and other labor-saving devices \[Archer, 2013\]. This has left adults living longer, yet weaker, less fit and more obese. In fact, most residents of nursing homes are not there because of dementia. Only 40% of long-term care facility residents in 2010 were diagnosed with dementia \[Caffrey, 2012\] and many of whom had a level of dementia which would not require nursing home placement by itself. Most residents of long-term care facilities, rather, are there because they lack the strength and fitness to care for themselves. As baby boomers retire, these factors are anticipated to greatly increase the need for long-term care, highlighted in a report from a Deloitte Consulting in 2010: "Medicaid Long-term Care: The ticking time bomb" \[Keckley, 2010\]. This pilot study will measure a significant increase in strength with the use of a 12 week strength training program.
The invention relates to a method of producing an injectable, self-setting calcium phosphate foam that is intended to be used as a biomaterial for bone regeneration and/or as a substrate for tissue engineering.  The inventive method comprises the foaming of a calcium phosphate cement with the addition of surface-active agents and the mechanical beating or stirring of same.  The addition of the surface-active agent enables the air bubbles in the cement matrix to be stabilised, thereby providing increased microporosity with interconnected pores.  Microporosity is of great importance for bone regeneration as it facilitates angiogenesis, colonisation of the material by bone tissue and reabsorption thereof.  The selection of biocompatible surface-active agents is particularly relevant taking account of the uses of the material.  As such, the invention makes use of surface-active agents that are approved for systems involving the parenteral dosing of drugs.
A method for treating an osteochondral defect or a chondral defect in a subject includes implanting a composite in a site of the osteochondral or chondral defect. The composite includes a hyaluronic acid derivative; and at least one member of the group consisting of a cell, a cellular growth factor and a cellular differentiation factor, which is impregnated in, or coupled to, the hyaluronic acid derivative. In one embodiment, carboxyl functionalities of the hyaluronic acid derivative are. each independently derivatized to include an N-acylurea or O-acyl isourea, or both N-acylurea and O-acyl isourea. In another embodiment, the hyaluronic acid derivative is prepared by reacting an uncrosslinked hyaluronic acid with a biscarbodimide in the presence of a pH buffer in a range of between about (4) and about (8). The composite can be used for regenerating or stimulating regeneration of meniscal tissues in a subject in need thereof.
This is a prospective, non-therapeutic study with two components: biopsy of tumor for genomic studies and prospective assessment of parental factors related to participation. All patients at St. Jude Children's Research Hospital (SJCRH) who meet the eligibility criteria will be approached for study participation. The re-biopsy is not mandatory and will only be performed after the patient and family have consented. A questionnaire to assess the impact and perception of an optional/research only biopsy will be administered following the decision regarding re-biopsy. For those consenting to the re-biopsy, approximately 4-8 weeks after biopsy, the family and patient will be asked to complete a second questionnaire to assess decisional regret.

Participants may repeat participation in this trial with subsequent relapses, provided informed consent is obtained prior to each re-biopsy procedure. For those participants who consent to repeat participation, all protocol procedures will be repeated.
The self-help mental fitness training camp, comprising 21 learning modules structured around animated thinking videos, audio, text, and moving images, lasts 21 days. Each learning module is automatically pushed to the intervention group on a daily basis, with an estimated completion time of 30-50 minutes.
Thumbtack intra-dermal needle will be applied to selected acupuncture points after filiform needle treatment. The thumbtack needle will remain embedded in the patient's dermal part for 2-3 days as per instruction.During the study period, a maximum of two courses of acupuncture therapy, consisting of 7 sessions each, will be administered. Treatment will be given twice per week. After completing the first course of 7 sessions, there will be a break of one week, at the end of which the second course will commence. Treatment will come to a halt as soon as the pain has totally subsided.
Metronidazole: Cases of encephalopathy and peripheral neuropathy (including optic neuropathy) have been reported with metronidazole: Encephalopathy has been reported in association with cerebellar toxicity characterized by ataxia, dizziness, and dysarthria. CNS lesions seen on MRI have been described in reports of encephalopathy. CNS symptoms are generally reversible within days to weeks upon discontinuation of metronidazole. CNS lesions seen on MRI have also been described as reversible; Peripheral neuropathy, mainly of sensory type has been reported and is characterized by numbness or paresthesia of an extremity. 

Convulsive seizures have been reported in patients treated with metronidazole.

Aseptic meningitis: Cases of aseptic meningitis have been reported with metronidazole. Symptoms can occur within hours of dose adiminstration and generally resolve after metronidazole therapy is discontinued. 

Tetracycline: Cases of pseudotumor cerebri in adults have been associated with the use of tetracycline. The usual clinical manifestations are headache and blurred vision. While this condition and related symptoms usually resolve soon after discontinuation of the tetracycline, the possibility for permanent sequelae exists. 

Bismuth-containing products: Cases of neurotoxicity associated with excessive doses of various bismuth-containing products have been reported. Effects have been reversible with discontinuation of bismuth therapy. 

The appearance of abnormal neurologic signs and symptoms demands the prompt evaluation of the benefit/risk ratio of the continuation of PYLERA therapy [See Adverse Reactions (6.3)]
Vaccine compositions contain an antigen and diethylaminoethyl dextran (DEAE-D) as adjuvant and antigen-containing vaccine compositions for active immunisation are potentiated by admixing DEAE-D with the vaccine. The vaccine may contain 5 to 250mg. per ml. of DEAE-D. The pH of the DEAE-D may be adjusted with a buffer and the DEAE-D and any buffer may be heated for 20-30 minutes at 110 to 120 C in an autoclave for sterilisation, and after cooling an antigen solution added thereto, thereby forming a vaccine. In examples, vaccines containing foot and mouth disease virus optionally inactivated with ethylethyleneimine and inactivated virus of infectious bovine Rhinotracheitis are employed. The vaccine compositions may contain other adjuvants such as Al(OH) 3 , saponin and. oil adjuvants.
This study aimed to evaluate the etiology and pregnancy outcomes of fetuses underwent invasive prenatal diagnosis for fetal growth restriction (FGR) accompanied by structural malformations. Data from 130 pregnancies referred for prenatal diagnosis for FGR accompanied by structural malformations were obtained between July 2011 and July 2023. Traditional karyotyping was conducted for all the subjects. A total of 37 (28.5%) cases of chromosomal abnormalities were detected by karyotyping, including 30 cases of numerical anomalies and seven cases of unbalanced structural anomalies. Trisomy 18 was the most common abnormalities, accounting for 51.4%, significantly higher than any other chromosomal abnormality. The cohort was predominantly comprised of early-onset FGR (88.5%) compared to late-onset FGR (11.5%). The incidences of chromosomal abnormalities in this two groups were 29.6% (34/115) and 20.0% (3/15), respectively (p > 0.05). The majority (74.6%, 97/130) of the cohort were affected by a single system malformation, with chromosomal abnormalities found in 19.6% (19/97) of cases. In pregnancies of structural malformations involving two and multiple systems, the frequencies were 56.5% (13/23), and 50.0% (5/10), respectively. Single nucleotide polymorphism array (SNP array) was performed in parallel for 65 cases, revealing additional 7.7% cases of copy number variants (CNVs) compared to karyotyping. Polymerase chain reaction (PCR) was used for detection of cytomegalovirus (CMV) DNA in 92 cases. All fetuses with FGR associated with two or more system malformations were either terminated or stillborn, irrespective of chromosomal aberrations. Conversely, 71.8% of pregnancies with a single-system malformation and normal genetic testing results resulted in live births. Furthermore, two (2.2%) cases tested positive for CMV DNA, leading to one termination and one case of serious developmental disorder after birth. Our study suggests that structural malformations associated with FGR are more likely to affect a single organ system. When multiple systems are involved, the incidence of chromosomal abnormalities and termination rates are notably high. We advocate for the use of CMA and CMV DNA examinations in FGR cases undergo invasive prenatal diagnosis, as these tests can provide valuable insights for etiological exploration and pregnancy management guidance.
Youth Participants with CKD will complete the 9 My Kidney Guru modules over the 6-month intervention period, at a rate of approximately one module every 2-3 weeks. Parent participants will complete the parent module within the first t2 weeks of the intervention period, and to review the remaining youth modules by the end of the trial period. Participants will complete outcomes measures within 1 month prior to beginning the intervention. Software usage data will be gathered regarding fidelity and dosage of the My Kidney Guru intervention. Within 1 month of completing the intervention period, participants will complete the same set of outcomes assessments, along with an evaluation survey of the intervention. Once post-intervention data collection has been completed and the intervention period has ended, participants will participate in a 45 minute follow up Web-Ex focus group to provide feedback on their experiences with My Kidney Guru and collect additional suggestions for improvement.
The present invention relates to a kind of steroid saponins compound and its preparation method. It not only possesses good therapeutic effect for curing cancers, but also has no toxic side effect. Its preparation method includes the following steps: using medicinal plant or Chinese medicinal material as raw material, adopting ethyl alcohol extraction and n-butanol extraction processes and utilizing the separation measures of polymeric adsorbent column chromatography, vacuum liquid-phase column chromatography, silica gel column chromatography. Sephadex column chromatography, medium-low pressure column chromatography and preparative HPLC, etc. to obtain the invented compound or adopting synthesis and partial synthesis to obtain one. It can be made into various dosage forms.
Participants will receive a nonmyeloablative conditioning regimen of fludarabine and busulfan prior to allogeneic peripheral blood stem cell (CD34+) infusions. FK506 and prednisone will be administered for graft versus host disease (GVHD) prophylaxis.
PCT No. PCT/FR92/00182 Sec. 371 Date Apr. 22, 1994 Sec. 102(e) Date Apr. 22, 1994 PCT Filed Feb. 27, 1992 PCT Pub. No. WO92/21321 PCT Pub. Date Dec. 10, 1992.A method for separating a composition containing glycolipids, lysopholipids, sphingolipids and ceramides of plant origin is described. A liquid alcohol is heated to a temperature of between 50 DEG  and 80 DEG  C., a plant composition or plant extract is introduced into the alcohol to form a mixture, the mixture is hot-filtered so as to separate the filtrate from a dilapidated filter cake, and the alcohol is evaporated from the filtrate such that a lipid residue which contains glycolipids, lysophospholipids, sphingolipids, and ceramides is obtained. The lipid residue can be used in cosmetology or dermatology.
Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the adolescent dose group 2 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.